Butaperazine

DB13213

small molecule approved

Deskripsi

Butaperazine was approved in 1967 L5143, and possibly discontinued in the 1980s T397.

Struktur Molekul 2D

Berat 409.59
Wujud -

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

824 Data
Buprenorphine Butaperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butaperazine.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Butaperazine.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Butaperazine.
Hydrocodone Butaperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Butaperazine.
Magnesium sulfate The therapeutic efficacy of Butaperazine can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Butaperazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Butaperazine.
Mirtazapine Butaperazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Butaperazine.
Orphenadrine Butaperazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Butaperazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Butaperazine.
Pramipexole Butaperazine may increase the sedative activities of Pramipexole.
Ropinirole Butaperazine may increase the sedative activities of Ropinirole.
Rotigotine Butaperazine may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Butaperazine.
Sodium oxybate Butaperazine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Butaperazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Butaperazine.
Thalidomide Butaperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Butaperazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Amisulpride Butaperazine may increase the antipsychotic activities of Amisulpride.
Methylphenidate The risk or severity of adverse effects can be increased when Butaperazine is combined with Methylphenidate.
Dexmethylphenidate The risk or severity of adverse effects can be increased when Butaperazine is combined with Dexmethylphenidate.
Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Butaperazine.
Quinagolide The therapeutic efficacy of Quinagolide can be decreased when used in combination with Butaperazine.
Sulpiride Butaperazine may increase the antipsychotic activities of Sulpiride.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Butaperazine.
Lithium citrate Lithium citrate may increase the neurotoxic activities of Butaperazine.
Lithium hydroxide Lithium hydroxide may increase the neurotoxic activities of Butaperazine.
Mequitazine Butaperazine may increase the arrhythmogenic activities of Mequitazine.
Tetrabenazine The risk or severity of adverse effects can be increased when Butaperazine is combined with Tetrabenazine.
Deutetrabenazine The risk or severity of adverse effects can be increased when Butaperazine is combined with Deutetrabenazine.
Thiopental The risk or severity of adverse effects can be increased when Butaperazine is combined with Thiopental.
Metyrosine The risk or severity of extrapyramidal symptoms and CNS depression can be increased when Metyrosine is combined with Butaperazine.
Ethanol Butaperazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Butaperazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Butaperazine.
Fluvoxamine The risk or severity of adverse effects can be increased when Butaperazine is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Butaperazine is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Butaperazine is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Butaperazine is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Butaperazine is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Butaperazine is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Butaperazine is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Butaperazine is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Butaperazine is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Butaperazine is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Butaperazine is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Butaperazine is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Butaperazine is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Butaperazine is combined with Seproxetine.
Levomilnacipran The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Butaperazine.
Indalpine The risk or severity of adverse effects can be increased when Butaperazine is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Butaperazine is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Butaperazine is combined with Alaproclate.
Esmolol The serum concentration of Esmolol can be increased when it is combined with Butaperazine.
Betaxolol The serum concentration of Betaxolol can be increased when it is combined with Butaperazine.
Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Butaperazine.
Atenolol The serum concentration of Atenolol can be increased when it is combined with Butaperazine.
Timolol The serum concentration of Timolol can be increased when it is combined with Butaperazine.
Sotalol The serum concentration of Sotalol can be increased when it is combined with Butaperazine.
Propranolol The serum concentration of Propranolol can be increased when it is combined with Butaperazine.
Labetalol The serum concentration of Labetalol can be increased when it is combined with Butaperazine.
Bisoprolol The serum concentration of Bisoprolol can be increased when it is combined with Butaperazine.
Alprenolol The serum concentration of Alprenolol can be increased when it is combined with Butaperazine.
Pindolol The serum concentration of Pindolol can be increased when it is combined with Butaperazine.
Carvedilol The serum concentration of Carvedilol can be increased when it is combined with Butaperazine.
Propafenone The serum concentration of Propafenone can be increased when it is combined with Butaperazine.
Acebutolol The serum concentration of Acebutolol can be increased when it is combined with Butaperazine.
Nadolol The serum concentration of Nadolol can be increased when it is combined with Butaperazine.
Bevantolol The serum concentration of Bevantolol can be increased when it is combined with Butaperazine.
Practolol The serum concentration of Practolol can be increased when it is combined with Butaperazine.
Penbutolol The serum concentration of Penbutolol can be increased when it is combined with Butaperazine.
Oxprenolol The serum concentration of Oxprenolol can be increased when it is combined with Butaperazine.
Dexpropranolol The serum concentration of Dexpropranolol can be increased when it is combined with Butaperazine.
Celiprolol The serum concentration of Celiprolol can be increased when it is combined with Butaperazine.
Nebivolol The serum concentration of Nebivolol can be increased when it is combined with Butaperazine.
Bufuralol The serum concentration of Bufuralol can be increased when it is combined with Butaperazine.
Bopindolol The serum concentration of Bopindolol can be increased when it is combined with Butaperazine.
Bupranolol The serum concentration of Bupranolol can be increased when it is combined with Butaperazine.
Indenolol The serum concentration of Indenolol can be increased when it is combined with Butaperazine.
Arotinolol The serum concentration of Arotinolol can be increased when it is combined with Butaperazine.
Levobetaxolol The serum concentration of Levobetaxolol can be increased when it is combined with Butaperazine.
Talinolol The serum concentration of Talinolol can be increased when it is combined with Butaperazine.
Anisodamine The serum concentration of Anisodamine can be increased when it is combined with Butaperazine.
Bucindolol The serum concentration of Bucindolol can be increased when it is combined with Butaperazine.
Esatenolol The serum concentration of Esatenolol can be increased when it is combined with Butaperazine.
Cloranolol The serum concentration of Cloranolol can be increased when it is combined with Butaperazine.
Mepindolol The serum concentration of Mepindolol can be increased when it is combined with Butaperazine.
Epanolol The serum concentration of Epanolol can be increased when it is combined with Butaperazine.
Tertatolol The serum concentration of Tertatolol can be increased when it is combined with Butaperazine.
Landiolol The serum concentration of Landiolol can be increased when it is combined with Butaperazine.
Morphine The risk or severity of hypotension and CNS depression can be increased when Butaperazine is combined with Morphine.
Codeine The risk or severity of hypotension and CNS depression can be increased when Butaperazine is combined with Codeine.
Hydromorphone The risk or severity of hypotension and CNS depression can be increased when Butaperazine is combined with Hydromorphone.
Meperidine The risk or severity of hypotension and CNS depression can be increased when Butaperazine is combined with Meperidine.
Oxycodone The risk or severity of hypotension and CNS depression can be increased when Butaperazine is combined with Oxycodone.

Referensi & Sumber

Textbook
  • ISBN: 1137490934
    8. (2015). In Psychiatry in Communist Europe. Palgrave Macmillan.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul